Anavex Life Sciences joins European initiative to accelerate Alzheimer's disease care.

Anavex Life Sciences Corp. is partnering with the European Commission's Innovative Health Initiative in the ACCESS-AD program to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease. The five-year program aims to strengthen equitable access to timely and effective AD care across real-world clinical settings. Recent approvals of antibody-based disease-modifying therapies have expanded the treatment landscape, but health systems face bottlenecks in diagnosis, patient stratification, imaging capacity, and ongoing monitoring.